Elena Prieto-Pareja
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Elena Prieto-Pareja has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Ana-Wu-Yang Yi-Shi
Departments of Pathology, Hospital Universitario Fundación Jiménez Díaz, 28040 Madrid, Spain
2 shared publications - Carlos Santonja
Department of Pathology, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
2 shared publications - Carlos Soto-De Ozaeta
Departments of Haematology, Hospital Universitario Fundación Jiménez Díaz, 28040 Madrid, Spain
2 shared publications - Cristina Serrano-Del Castillo
Departments of Haematology, Hospital Universitario Fundación Jiménez Díaz, 28040 Madrid, Spain
2 shared publications - Daniel Morillo-Giles
Lymphoma Unit, Department of Hematology, Fundación Jiménez Díaz University Hospital, IIS-FJD Health Research Institute, Avenida Reyes Catolicos, 228040 Madrid, Spain
2 shared publications - Rebeca Manso
Pathology Department, Health Research Institute-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain
2 shared publications
Latest Publications
- Open Access
Leukaemic Presentation of Small-Cell Alk-Positive Anaplastic Large Cell Lymphoma in a Young Woman—Report of a Case with 9-Year Survival
Anaplastic large cell lymphoma (ALCL) with leukaemic presentation (either ab initio or along the course of the disease) has been rarely reported. Irrespective of ALK expression in the neoplastic cells, it features a dismal prognosis. We report a rare case of leukaemic, small cell variant ALK-positive ALCL with 9-year survival in a young woman who was treated upfront with corticosteroids and standard chemotherapy, and review thoroughly the previously published cases. Such an unexpected, good outcome hints at the existence of different clinical subgroups in the leukaemic variant of ALK-positive ALCL.
Open AccessLeukaemic Presentation of Small-Cell Alk-Positive Anaplastic Large Cell Lymphoma in a Young Woman—Report of a Case with 9-Year Survival
Anaplastic large cell lymphoma (ALCL) with leukaemic presentation (either ab initio or along the course of the disease) has been rarely reported. Irrespective of ALK expression in the neoplastic cells, it features a dismal prognosis. We report a rare case of leukaemic, small cell variant ALK-positive ALCL with 9-year survival in a young woman who was treated upfront with corticosteroids and standard chemotherapy, and review thoroughly the previously published cases. Such an unexpected, good outcome hints at the existence of different clinical subgroups in the leukaemic variant of ALK-positive ALCL.
- Open Access
- 13 July 2023
- Published by MDPI AG in Preprints.org
LEUKAEMIC PRESENTATION OF SMALL-CELL ALK-POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA IN A YOUNG WOMAN. REPORT OF A CASE WITH 9-YEAR SURVIVAL.
Anaplastic large cell lymphoma (ALCL) with leukemic presentation (either ab initio or along the course of the disease) has been rarely reported. Irrespective of ALK-status in the neoplastic cells, it features a dismal prognosis. We report a case of leukemic, ALK-positive ALCL with 9-year survival in a young woman who was treated upfront with corticosteroids and standard chemotherapy, and review thoroughly the previously published cases. Such an unexpected, good outcome hints at the existence of different clinical subgroups in the leukemic variant of ALCL.
- 13 July 2023
- Published by MDPI AG in Preprints.org
Open AccessLEUKAEMIC PRESENTATION OF SMALL-CELL ALK-POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA IN A YOUNG WOMAN. REPORT OF A CASE WITH 9-YEAR SURVIVAL.
Anaplastic large cell lymphoma (ALCL) with leukemic presentation (either ab initio or along the course of the disease) has been rarely reported. Irrespective of ALK-status in the neoplastic cells, it features a dismal prognosis. We report a case of leukemic, ALK-positive ALCL with 9-year survival in a young woman who was treated upfront with corticosteroids and standard chemotherapy, and review thoroughly the previously published cases. Such an unexpected, good outcome hints at the existence of different clinical subgroups in the leukemic variant of ALCL.